Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBITDA Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBITDA Margin for 10 consecutive years, with 15.77% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 1167.0% year-over-year to 15.77%, compared with a TTM value of 17.37% through Sep 2025, down 444.0%, and an annual FY2024 reading of 19.1%, down 261.0% over the prior year.
  • EBITDA Margin was 15.77% for Q3 2025 at Sunshine Biopharma, down from 7.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 777.1% in Q4 2021 and bottomed at 15445.58% in Q1 2021.
  • Average EBITDA Margin over 5 years is 1654.43%, with a median of 24.23% recorded in 2024.
  • The sharpest move saw EBITDA Margin tumbled -1458447bps in 2021, then soared 1443842bps in 2022.
  • Year by year, EBITDA Margin stood at 777.1% in 2021, then crashed by -176bps to 590.65% in 2022, then skyrocketed by 98bps to 9.88% in 2023, then crashed by -233bps to 32.9% in 2024, then skyrocketed by 52bps to 15.77% in 2025.
  • Business Quant data shows EBITDA Margin for SBFM at 15.77% in Q3 2025, 7.29% in Q2 2025, and 12.96% in Q1 2025.